science
plus
.abes.fr
|
explorer
À propos de :
Raffi François
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
foaf:Person
, within Data Space :
scienceplus.abes.fr
associated with source
document(s)
Type:
Person
New Facet based on Instances of this Class
Attributs
Valeurs
type
Person
name
Raffi François
Raffi Franæois
personal mailbox
francois.raffi@wanadoo.fr
familyName
Raffi
Given name
François
Franæois
is
relates
of
http://hub.abes.fr/oup/periodical/cid/2000/volume_31/issue_5/101086317424/authorship/1
http://hub.abes.fr/oup/periodical/cid/2002/volume_34/issue_2/101086324354/authorship/9
http://hub.abes.fr/oup/periodical/cid/2002/volume_35/issue_1/101086340713/authorship/5
http://hub.abes.fr/oup/periodical/jid/2002/volume_185/issue_4/101086338929/authorship/9
http://hub.abes.fr/oup/periodical/jac/2010/volume_65/issue_5/101093jacdkq084/authorship/6
http://hub.abes.fr/oup/periodical/cid/2004/volume_39/issue_2/101086422141/authorship/11
http://hub.abes.fr/oup/periodical/jac/2008/volume_61/issue_6/101093jacdkn098/authorship/7
http://hub.abes.fr/oup/periodical/cid/2001/volume_32/issue_6/101086319368/authorship/4
is
Author
of
Substitution of a Nonnucleoside Reverse Transcriptase Inhibitor for a Protease Inhibitor in the Treatment of Patients with Undetectable Plasma Human Immunodeficiency Virus Type 1 RNA
Incidence of and Risk Factors for Adverse Drug Reactions in a Prospective Cohort of HIV-Infected Adults Initiating Protease Inhibitor—Containing Therapy
Predictors of Long-Term Increase in CD4+ Cell Counts in Human Immunodeficiency Virus-Infected Patients Receiving a Protease Inhibitor-Containing Antiretroviral Regimen
Impact of Discontinuation of Initial Protease Inhibitor Therapy on Further Virological Response in a Cohort of Human Immunodeficiency Virus-Infected Patients
Legionella pneumophila Arthritis: Use of Medium Specific for Mycobacteria for Isolation of L. pneumophila in Culture of Articular Fluid Specimens
Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial
Evaluation of Chronic Hepatitis B Virus (HBV) Infection in Coinfected Patients Receiving Lamivudine as a Component of Anti-Human Immunodeficiency Virus Regimens
Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine
Alternative Linked Data Documents:
ODE
Content Formats:
RDF
ODATA
Microdata
